Hansoh Xinfu (flumatinib)

However, when acting as a victim, co-administration with strong CYP3A4 inhibitors (itraconazole, ketoconazole) increased flumatinib AUC0-72h by approximately 12-fold (AUCR = 11.65-12.96), whereas rifampicin decreased Cmax and AUC0-72h by 2.4- and 4.7-fold (CmaxR = 0.41, AUCR = 0.21), respectively. Flumatinib shows negligible perpetrator potential but is highly sensitive to CYP3A4 modulation. PBPK-informed DDI assessment supports cautious co-administration with strong CYP3A4 inhibitors or inducers and guides its rational clinical use.

Flumatinib likewise lowered MTX clearance and raised ≥ grade 2 nephrotoxicity to 29.4%, yet neither effect reached statistical significance. Temporary withdrawal of olverembatinib before HD-MTX infusion may prevent MTX-related nephrotoxicity.

Here, we report that inhibition of c-Abl with flumatinib mesylate significantly impairs the survival rate and exacerbates fungal burden in mice infected with Candida albicans...Collectively, our study uncovers a c-Abl/c-Cbl/MAPK signaling axis in dendritic cells that governs antifungal innate immunity, highlighting c-Cbl as a critical downstream mediator linking c-Abl to host defense against C. albicans. Our findings provide a mechanistic basis for fungal risk assessment in cancer patients treated with c-Abl inhibitors.

TKIs, including flumatinib, may cause AKI; however, FAERS-based disproportionality analysis does not indicate an increased renal safety signal compared to non-TKIs. Among TKIs, dasatinib and nilotinib have lower reporting disproportionality than imatinib does, suggesting a potential therapeutic advantage of their use for patients with kidney diseases.

The patient achieved deep molecular remission of chronic-phase CML (BCR::ABL1 0.0058% International Scale) while receiving flumatinib, yet developed a painful sacrococcygeal mass...Intermediate-dose cytarabine with continued tyrosine-kinase inhibition produced marked metabolic regression on PET-CT, and the patient has been bridged to allogeneic hematopoietic stem-cell transplantation...Co-occurrence of BCR::ABL1 and NPM1::CCDC28A may delineate a distinct EMBC subset with prognostic and therapeutic relevance. Prospective studies are required to clarify the fusion's pathogenic role and biomarker potential.

This report described a CML patient with a rare e8a2 BCR::ABL1 transcript variant, who also presented with difficult-to-correct iron-deficiency anemia. The patient was treated with Flumatinib and achieved complete hematologic remission at 1 month, complete cytogenetic remission at 3 months, and major molecular remission at 6 months.

FLU combined with CHI synergistically inhibits cell proliferation, promotes apoptosis, and induces cycle arrest by targeting the PI3K/AKT signaling pathway through the p53/c-Myc axis in Ph+ ALL.

P1/2, N=330, Recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Flumatinib-based regimens demonstrated high efficacy and tolerable toxicity in Ph+ ALL, which was comparable to other second-generation TKIs. T315I and Y253H mutations were key drivers of relapse. Although allo-HSCT enhanced survival, longer follow-up period and prospective trials are warranted to validate these findings.

In addition, elevated alanine aminotransferase or aspartate aminotransferase (ALT/AST), glucose, and serum lipid; hyperbilirubinemia; rash; and alopecia were more frequent among patients receiving nilotinib, whereas diarrhea was more frequent in those receiving flumatinib. Flumatinib is a suitable alternative as a first-line treatment for patients with CML-CP to achieve a fast MMR with better tolerability.

P4, N=39, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=238 --> 39 | Recruiting --> Terminated; terminated

In the current case, the BCR-ABL fusion was detected and CML was confirmed after the recurrence of splenomegaly. Subsequent treatment with a combination of flumatinib and ruxolitinib was demonstrated to be safe and effective.